Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kenneth Stallman

Urology San Antonio, TX Medical Doctor

NPI 1871575100 CMS profile 39948

7909 Fredericksburg Rd Ste 125, San Antonio, TX 78229

Open in the dashboard

General payments

$5,488

33 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$340,124

7 holdings reported · through program year 2025

Research they led as principal investigator

$1,305,090 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Kenneth Stallman of San Antonio, TX is reported in the CMS Open Payments database as having received $5,488 across 33 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,305,090 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $340,124 across 7 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 67th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $328 6
2024 General $3,715 11
2023 General $281 3
2022 General $110 1
2021 General $142 1
2020 General $42 1
2019 General $871 10
2024 Ownership $75,371 2
2023 Ownership $73,895 1
2022 Ownership $35,673 1
2021 Ownership $33,125 1
2020 Ownership $84,936 1
2019 Ownership $37,124 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kenneth Stallman
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Kenneth Stallman were reported at $328. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Kenneth Stallman Urology median Middle half National median
2019 $871 $480 $147–$1,201 $163
2020 $42 $246 $87–$645 $114
2021 $142 $358 $111–$1,000 $132
2022 $110 $476 $143–$1,263 $149
2023 $281 $560 $168–$1,461 $160
2024 $3,715 $563 $170–$1,464 $164
2025 $328 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $4,723 18 payments
  2. SN Holdings, LLC $142 1 payment
  3. Profound Medical Corp. $141 1 payment
  4. TissueTech, Inc. $110 1 payment
  5. AngioDynamics, Inc. $74 1 payment
  6. Novartis Pharmaceuticals Corporation $62 2 payments
  7. Blue Earth Diagnostics Limited $54 2 payments
  8. Sumitomo Pharma America, Inc. $51 2 payments
  9. Dornier MedTech America, Inc $42 1 payment
  10. AstraZeneca Pharmaceuticals LP $29 1 payment
  11. Other $60 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $3,000 2 payments
  2. Travel and Lodging $1,581 12 payments
  3. Food and Beverage $906 19 payments
Products named General payments · program years 2019–2025
  1. DA VINCI SP $3,000 2 payments
  2. Da Vinci Surgical System $1,723 16 payments
  3. Tulsa-Pro $141 1 payment
  4. NEOX $110 1 payment
  5. CLARIX $110 1 payment
  6. AURYON LASER SYSTEM 100-120 VAC $74 1 payment
  7. PLUVICTO $62 2 payments
  8. POSLUMA $54 2 payments
  9. GEMTESA $51 2 payments
  10. Lithotripters & Accessories $42 1 payment
  11. Other $119 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

2,506

Median for Urology: 1,053

Drug cost

$3,960,008

Median for Urology: $101,464

Branded share of claims

36.2%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Erleada Apalutamide Brand 173 $2,450,582
Xtandi Enzalutamide Brand 37 $527,743
Nubeqa Darolutamide Brand 24 $314,700
Orgovyx Relugolix Brand 116 $300,337
Trelstar Triptorelin Pamoate Brand 61 $143,254
Myrbetriq Mirabegron Brand 91 $98,020
Gemtesa Vibegron Brand 62 $50,799
Nilutamide Generic 12 $27,005
Tamsulosin Hcl Generic 840 $13,053
Solifenacin Succinate Generic 159 $8,636

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$415,928

Of which drugs: $199,942

Medicare patients

905

Average age 75

Services billed

10,438

155 women, 750 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 48%
Arthritis 42%
Ischemic heart disease 40%
Diabetes 35%
Chronic kidney disease 33%
Atrial fibrillation 19%
Heart failure 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 22 5,160 $100,738
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 21 93 $12,498

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LYNPARZA
  • AstraZeneca Pharmaceuticals LP $29
$29 — —
POSLUMA
  • Blue Earth Diagnostics Limited $24
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

33 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record